Related references
Note: Only part of the references are listed.Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial
Jun Tian et al.
NATURE MEDICINE (2023)
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer
Sophie Leboulleux et al.
CLINICAL CANCER RESEARCH (2023)
Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer
Juanjuan Feng et al.
ACTA PHARMACEUTICA SINICA B (2023)
Lessons from clinical trials on triple combination of immune checkpoint inhibitors and BRAF/MEK inhibitors in BRAF-mutant melanoma
Takuya Maeda et al.
Annals of Translational Medicine (2023)
Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials
Yanlin Song et al.
GENES & DISEASES (2023)
MAPK Pathway Inhibitors in Thyroid Cancer: Preclinical and Clinical Data
Louis Schubert et al.
CANCERS (2023)
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma
Reinhard Dummer et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment
Sara G. Manore et al.
FRONTIERS IN ONCOLOGY (2022)
Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
Aayoung Hong et al.
CANCER DISCOVERY (2021)
IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
Hima Patel et al.
CANCERS (2021)
Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
Beike Wang et al.
ONCOGENE (2021)
TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitors
Erica Aparecida de Oliveira et al.
PHARMACOLOGICAL RESEARCH (2021)
BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer
Gary Middleton et al.
CLINICAL CANCER RESEARCH (2020)
Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro
Timothy M. Ullmann et al.
SURGERY (2020)
Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis
Dan A. Erkes et al.
CANCER DISCOVERY (2020)
Mutations That Confer Drug-Resistance, Oncogenicity and Intrinsic Activity on the ERK MAP Kinases-Current State of the Art
Karina Smorodinsky-Atias et al.
CELLS (2020)
Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors
Maria E. Cabanillas et al.
THYROID (2020)
Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway
Pui-Kei Wu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H
April K. S. Salama et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
Reinhard Dummer et al.
NATURE MEDICINE (2020)
Resistance mechanism of the oncogenic β3-αC deletion mutation in BRAF kinase to dabrafenib and vemurafenib revealed by molecular dynamics simulations and binding free energy calculations
Yuzhen Niu et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2019)
Mitochondrial metabolism is inhibited by the HIF1-MYC-PGC-1 axis in BRAF V600E thyroid cancer
Yanyan Gao et al.
FEBS JOURNAL (2019)
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Paolo Antonio Ascierto et al.
NATURE MEDICINE (2019)
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas et al.
NATURE MEDICINE (2019)
Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency
Mehwish Khaliq et al.
CANCERS (2019)
Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma
Eva A. Ebbing et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma
Rani Ojha et al.
CANCER DISCOVERY (2019)
Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
Liang Cheng et al.
MODERN PATHOLOGY (2018)
Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition
Manali Phadke et al.
MOLECULAR ONCOLOGY (2018)
BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy
Douglas B. Johnson et al.
PIGMENT CELL & MELANOMA RESEARCH (2018)
Prevalence and Clinicopathologic Significance of BRAF V600E Mutation in Chinese Multiple Myeloma Patients
Coty H. Y. Cheung et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Desmoplastic Infantile Ganglioglioma/Astrocytoma (DIG/DIA) Are Distinct Entities with Frequent BRAFV600 Mutations
Anthony C. Wang et al.
MOLECULAR CANCER RESEARCH (2018)
AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma
Qiang Zuo et al.
ONCOGENE (2018)
Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in &ITBRAF&ITV600E Colorectal Cancer
Mehlika Hazar-Rethinam et al.
CANCER DISCOVERY (2018)
Evolution of melanoma cross-resistance to CD8+ T cells and MAPK inhibition in the course of BRAFi treatment
Natalia Pieper et al.
ONCOIMMUNOLOGY (2018)
Immunological effects of BRAF plus MEK inhibition
Paolo A. Ascierto et al.
ONCOIMMUNOLOGY (2018)
New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging
Hailey E. Brighton et al.
CANCER RESEARCH (2018)
BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression
David Barras et al.
CLINICAL CANCER RESEARCH (2017)
Cancer drug addiction is relayed by an ERK2-dependent phenotype switch
Xiangjun Kong et al.
NATURE (2017)
Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells
Matthew L. Fisher et al.
ONCOTARGET (2017)
New perspectives for targeting RAF kinase in human cancer
Zoi Karoulia et al.
NATURE REVIEWS CANCER (2017)
Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation
Min Hwan Kim et al.
EMBO JOURNAL (2016)
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2
Scott A. Foster et al.
CANCER CELL (2016)
Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy
Michael P. Smith et al.
CANCER CELL (2016)
ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP
Taru Muranen et al.
CANCER RESEARCH (2016)
Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer
Daniele Oddo et al.
CANCER RESEARCH (2016)
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors
Gao Zhang et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer
Hidenori Kitai et al.
CANCER DISCOVERY (2016)
Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120
Shih-Hsun Chen et al.
CANCER DISCOVERY (2016)
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
Willy Hugo et al.
CELL (2015)
Genomic Classification of Cutaneous Melanoma
Rehan Akbani et al.
CELL (2015)
Active ERK2 is sufficient to mediate growth arrest and differentiation signaling
Pui-Kei Wu et al.
FEBS JOURNAL (2015)
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer
Ryan B. Corcoran et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long et al.
LANCET (2015)
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Luping Lin et al.
NATURE GENETICS (2015)
BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model
Daniele Perna et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma
Rachel Ramsdale et al.
SCIENCE SIGNALING (2015)
MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms
Pui-Kei Wu et al.
SEMINARS IN ONCOLOGY (2015)
BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis
E. H. Rustad et al.
BLOOD CANCER JOURNAL (2015)
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations
Leanne G. Ahronian et al.
CANCER DISCOVERY (2015)
Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma
Neel M. Fofaria et al.
ONCOTARGET (2015)
Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma
Luigi Fattore et al.
ONCOTARGET (2015)
The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma
Rachel Ramsdale et al.
SCIENCE SIGNALING (2015)
Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations
Michaela Angelika Ihle et al.
BMC CANCER (2014)
Molecular Pathways: BRAF Induces Bioenergetic Adaptation by Attenuating Oxidative Phosphorylation
Rizwan Haq et al.
CLINICAL CANCER RESEARCH (2014)
BRAF alterations in brain tumours: molecular pathology and therapeutic opportunities
Anna Sophie Berghoff et al.
CURRENT OPINION IN NEUROLOGY (2014)
Mitogen-activated Protein Kinase (MAPK) Hyperactivation and Enhanced NRAS Expression Drive Acquired Vemurafenib Resistance in V600E BRAF Melanoma Cells
Michael Lidsky et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147
Wilson I. Gonsalves et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies
Lise Boussemart et al.
NATURE (2014)
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
Georgina V. Long et al.
NATURE COMMUNICATIONS (2014)
A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
Hubing Shi et al.
CANCER DISCOVERY (2014)
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Hubing Shi et al.
CANCER DISCOVERY (2014)
MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
Nikhil Wagle et al.
CANCER DISCOVERY (2014)
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Eliezer M. Van Allen et al.
CANCER DISCOVERY (2014)
Towards a Unified Model of RAF Inhibitor Resistance
David B. Solit et al.
CANCER DISCOVERY (2014)
The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNFα
Michael P. Smith et al.
CANCER DISCOVERY (2014)
Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF
Rizwan Haq et al.
CANCER CELL (2013)
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
Dennie T. Frederick et al.
CLINICAL CANCER RESEARCH (2013)
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
Cory M. Johannessen et al.
NATURE (2013)
Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
Maria R. Girotti et al.
CANCER DISCOVERY (2013)
Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas
Cristina Montero-Conde et al.
CANCER DISCOVERY (2013)
Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
Piro Lito et al.
CANCER CELL (2012)
BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma
Y. Shao et al.
CELL DEATH AND DIFFERENTIATION (2012)
Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
Alexander M. Menzies et al.
CLINICAL CANCER RESEARCH (2012)
BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance
Alexander Marzuka Alcala et al.
CLINICAL CANCER RESEARCH (2012)
SHOC2 and CRAF Mediate ERK1/2 Reactivation in Mutant NRAS-mediated Resistance to RAF Inhibitor
Fred M. Kaplan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma
Vipin Yadav et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
James G. Greger et al.
MOLECULAR CANCER THERAPEUTICS (2012)
ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
Georgia Hatzivassiliou et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma
Genevieve Schindler et al.
ACTA NEUROPATHOLOGICA (2011)
Resistance to BRAF Inhibitors: Unraveling Mechanisms and Future Treatment Options
Jessie Villanueva et al.
CANCER RESEARCH (2011)
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Nikhil Wagle et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Biological challenges of BRAF inhibitor therapy
Igor Puzanov et al.
MOLECULAR ONCOLOGY (2011)
BRAF Mutations in Hairy-Cell Leukemia
Enrico Tiacci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Resistance to BRAF Inhibition in Melanomas
David B. Solit et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells
Annette S. Little et al.
SCIENCE SIGNALING (2011)
A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors
Andrey Loboda et al.
BMC MEDICAL GENOMICS (2010)
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
K. H. T. Paraiso et al.
BRITISH JOURNAL OF CANCER (2010)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Jonathan R. Dry et al.
CANCER RESEARCH (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M. Johannessen et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation
Ryan B. Corcoran et al.
SCIENCE SIGNALING (2010)
MEK1 mutations confer resistance to MEK and B-RAF inhibition
Caroline M. Emery et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Isolation of Intrinsically Active (MEK-independent) Variants of the ERK Family of Mitogen-activated Protein (MAP) Kinases
Vered Levin-Salomon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells
Elisa Sala et al.
MOLECULAR CANCER RESEARCH (2008)
The gatekeeper residue controls autoactivation of ERK2 via a pathway of intramolecular connectivity
Michelle A. Emrick et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
MAP-quest: Could we produce constitutively active variants of MAP kinases?
Nadav Askari et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2006)
Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma
A Tannapfel et al.
GUT (2003)
BRAF mutation in papillary thyroid carcinoma
J Cohen et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Constitutive activation of extracellular signal-regulated kinase 2 by synergistic point mutations
MA Emrick et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
